Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

Université Laval

$17,500.00

Delivery of Therapeutic Nucleic and Protein Structures Using Extracellular Vesicles

EF 2019-20

Résumé
"Recent developments in gene therapies offer great opportunities to treat hereditary diseases. Currently, Adeno-Associated Viruses (AAVs) are being used in hundreds of such clinical trials. These viral particles transport DNA to cells to repair or replace the gene responsible for a disease. While the treatments have achieved remarkable successes in recent years, the exorbitant costs, potential to trigger an immune reaction, and small carrying capacity inherent to viruses such as AAVs prevent them from being an ideal vector for these treatments. As such, my project will attempt to develop a new, more affordable, and safer type of vector based on extracellular vesicles (EVs) isolated from the patients themselves. These structures are normally used to transport proteins, RNA, and DNA from cell to cell and can be found all throughout the body. Since this is the case, they can be isolated in large quantities from a patient's blood and theoretically co-opted for the purposes of creating a gene therapy. Thus the objective of this project is to purify EVs from a patient's serum and introduce within them a Cas9 nuclease protein along with one or two single guide RNAs (sgRNAs) to produce a proof-of-concept EV-delivered gene therapy. These two elements are a part of the CRISPR/Cas9 system which is renowned for its capacity to target and cleave specific nucleic acid sequences. Our hypothesis is that by introducing within the EVs the Cas9/sgRNA ribonucleoprotein (RNP) complex, we will be able to deliver all of the components required to modify a cell's genome initially in cells in a dish and subsequently to mouse cells in vivo. Our results will permit the development of new treatments for diseases like Alzheimer's disease and muscular dystrophy using EVs as the delivery system "
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
428913
Name
Lamothe Gabriel
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Delivery of Therapeutic Nucleic and Protein Structures Using Extracellular Vesicles
Programtype2
Studentship Programs
Orgnameinp2
Université Laval
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cell Culture; Crispr/Cas9; Extracellular Vesicles; Gene Therapy; In Vitro Experiments; In Vivo Experiments; Mammalian Cell Lines; Systemic Delivery
Abstract
"Recent developments in gene therapies offer great opportunities to treat hereditary diseases. Currently, Adeno-Associated Viruses (AAVs) are being used in hundreds of such clinical trials. These viral particles transport DNA to cells to repair or replace the gene responsible for a disease. While the treatments have achieved remarkable successes in recent years, the exorbitant costs, potential to trigger an immune reaction, and small carrying capacity inherent to viruses such as AAVs prevent them from being an ideal vector for these treatments. As such, my project will attempt to develop a new, more affordable, and safer type of vector based on extracellular vesicles (EVs) isolated from the patients themselves. These structures are normally used to transport proteins, RNA, and DNA from cell to cell and can be found all throughout the body. Since this is the case, they can be isolated in large quantities from a patient's blood and theoretically co-opted for the purposes of creating a gene therapy. Thus the objective of this project is to purify EVs from a patient's serum and introduce within them a Cas9 nuclease protein along with one or two single guide RNAs (sgRNAs) to produce a proof-of-concept EV-delivered gene therapy. These two elements are a part of the CRISPR/Cas9 system which is renowned for its capacity to target and cleave specific nucleic acid sequences. Our hypothesis is that by introducing within the EVs the Cas9/sgRNA ribonucleoprotein (RNP) complex, we will be able to deliver all of the components required to modify a cell's genome initially in cells in a dish and subsequently to mouse cells <em>in vivo</em>. Our results will permit the development of new treatments for diseases like Alzheimer's disease and muscular dystrophy using EVs as the delivery system "
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lamothe, Gabriel
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~